Human Amniotic Fluid Stem Cells: Therapeutic Potential for Perinatal Patients with Intractable Neurological Disease

Daigo Ochiai, Hirotaka Masuda, Yushi Abe, Toshimitsu Otani, Marie Fukutake, Tadashi Matsumoto, Kei Miyakoshi, Mamoru Tanaka

研究成果: Article

2 引用 (Scopus)

抄録

Mesenchymal stem cells (MSCs) have generated great interest in the fields of regenerative medicine and immunotherapy because of their unique biological properties. Among MSCs, amniotic fluid stem cells (AFS) have a number of characteristics that make them attractive candidates for tissue engineering and cell replacement strategies, particularly for perinatal medicine. If various neonatal conditions, including birth asphyxia, preterm birth, and congenital abnormalities, which result in long-lasting severe impairments, could be predicted during pregnancy, it would allow collection of small samples of amniotic fluid cells by amniocentesis. In vitro culture of these autologous AFS during pregnancy would make them available for use soon after birth. Hypoxic-ischemic encephalopathy (HIE) and myelomeningocele (MMC) are neonatal conditions that cause permanent neurological disability, for which the treatment options are extremely limited. Experiments using animal models of HIE and MMC and human clinical trials have demonstrated that MSCs, including AFS, have beneficial effects on the central nervous system through paracrine influences, indicating that autologous AFS treatment may be applicable for intractable neurological diseases, including HIE and MMC, during the perinatal period. In this review, we focus on recent research related to the therapeutic potential of AFS for perinatal neurological diseases such as HIE and MMC.

元の言語English
ページ(範囲)57-66
ページ数10
ジャーナルThe Keio journal of medicine
67
発行部数4
DOI
出版物ステータスPublished - 2018 12 26

Fingerprint

Amniotic Fluid
Brain Hypoxia-Ischemia
Meningomyelocele
Stem Cells
Mesenchymal Stromal Cells
Therapeutics
Parturition
Pregnancy
Regenerative Medicine
Amniocentesis
Asphyxia
Premature Birth
Tissue Engineering
Immunotherapy
Central Nervous System
Animal Models
Medicine
Clinical Trials
Research

ASJC Scopus subject areas

  • Medicine(all)

これを引用

Human Amniotic Fluid Stem Cells : Therapeutic Potential for Perinatal Patients with Intractable Neurological Disease. / Ochiai, Daigo; Masuda, Hirotaka; Abe, Yushi; Otani, Toshimitsu; Fukutake, Marie; Matsumoto, Tadashi; Miyakoshi, Kei; Tanaka, Mamoru.

:: The Keio journal of medicine, 巻 67, 番号 4, 26.12.2018, p. 57-66.

研究成果: Article

Ochiai, Daigo ; Masuda, Hirotaka ; Abe, Yushi ; Otani, Toshimitsu ; Fukutake, Marie ; Matsumoto, Tadashi ; Miyakoshi, Kei ; Tanaka, Mamoru. / Human Amniotic Fluid Stem Cells : Therapeutic Potential for Perinatal Patients with Intractable Neurological Disease. :: The Keio journal of medicine. 2018 ; 巻 67, 番号 4. pp. 57-66.
@article{9fead780b4ca4ee2bc49786c5f53e263,
title = "Human Amniotic Fluid Stem Cells: Therapeutic Potential for Perinatal Patients with Intractable Neurological Disease",
abstract = "Mesenchymal stem cells (MSCs) have generated great interest in the fields of regenerative medicine and immunotherapy because of their unique biological properties. Among MSCs, amniotic fluid stem cells (AFS) have a number of characteristics that make them attractive candidates for tissue engineering and cell replacement strategies, particularly for perinatal medicine. If various neonatal conditions, including birth asphyxia, preterm birth, and congenital abnormalities, which result in long-lasting severe impairments, could be predicted during pregnancy, it would allow collection of small samples of amniotic fluid cells by amniocentesis. In vitro culture of these autologous AFS during pregnancy would make them available for use soon after birth. Hypoxic-ischemic encephalopathy (HIE) and myelomeningocele (MMC) are neonatal conditions that cause permanent neurological disability, for which the treatment options are extremely limited. Experiments using animal models of HIE and MMC and human clinical trials have demonstrated that MSCs, including AFS, have beneficial effects on the central nervous system through paracrine influences, indicating that autologous AFS treatment may be applicable for intractable neurological diseases, including HIE and MMC, during the perinatal period. In this review, we focus on recent research related to the therapeutic potential of AFS for perinatal neurological diseases such as HIE and MMC.",
keywords = "amniotic fluid stem cells, hypoxic-ischemic encephalopathy, mesenchymal stem cells, myelomeningocele, perinatal medicine",
author = "Daigo Ochiai and Hirotaka Masuda and Yushi Abe and Toshimitsu Otani and Marie Fukutake and Tadashi Matsumoto and Kei Miyakoshi and Mamoru Tanaka",
year = "2018",
month = "12",
day = "26",
doi = "10.2302/kjm.2017-0019-IR",
language = "English",
volume = "67",
pages = "57--66",
journal = "Keio Journal of Medicine",
issn = "0022-9717",
publisher = "Keio University School of Medicine",
number = "4",

}

TY - JOUR

T1 - Human Amniotic Fluid Stem Cells

T2 - Therapeutic Potential for Perinatal Patients with Intractable Neurological Disease

AU - Ochiai, Daigo

AU - Masuda, Hirotaka

AU - Abe, Yushi

AU - Otani, Toshimitsu

AU - Fukutake, Marie

AU - Matsumoto, Tadashi

AU - Miyakoshi, Kei

AU - Tanaka, Mamoru

PY - 2018/12/26

Y1 - 2018/12/26

N2 - Mesenchymal stem cells (MSCs) have generated great interest in the fields of regenerative medicine and immunotherapy because of their unique biological properties. Among MSCs, amniotic fluid stem cells (AFS) have a number of characteristics that make them attractive candidates for tissue engineering and cell replacement strategies, particularly for perinatal medicine. If various neonatal conditions, including birth asphyxia, preterm birth, and congenital abnormalities, which result in long-lasting severe impairments, could be predicted during pregnancy, it would allow collection of small samples of amniotic fluid cells by amniocentesis. In vitro culture of these autologous AFS during pregnancy would make them available for use soon after birth. Hypoxic-ischemic encephalopathy (HIE) and myelomeningocele (MMC) are neonatal conditions that cause permanent neurological disability, for which the treatment options are extremely limited. Experiments using animal models of HIE and MMC and human clinical trials have demonstrated that MSCs, including AFS, have beneficial effects on the central nervous system through paracrine influences, indicating that autologous AFS treatment may be applicable for intractable neurological diseases, including HIE and MMC, during the perinatal period. In this review, we focus on recent research related to the therapeutic potential of AFS for perinatal neurological diseases such as HIE and MMC.

AB - Mesenchymal stem cells (MSCs) have generated great interest in the fields of regenerative medicine and immunotherapy because of their unique biological properties. Among MSCs, amniotic fluid stem cells (AFS) have a number of characteristics that make them attractive candidates for tissue engineering and cell replacement strategies, particularly for perinatal medicine. If various neonatal conditions, including birth asphyxia, preterm birth, and congenital abnormalities, which result in long-lasting severe impairments, could be predicted during pregnancy, it would allow collection of small samples of amniotic fluid cells by amniocentesis. In vitro culture of these autologous AFS during pregnancy would make them available for use soon after birth. Hypoxic-ischemic encephalopathy (HIE) and myelomeningocele (MMC) are neonatal conditions that cause permanent neurological disability, for which the treatment options are extremely limited. Experiments using animal models of HIE and MMC and human clinical trials have demonstrated that MSCs, including AFS, have beneficial effects on the central nervous system through paracrine influences, indicating that autologous AFS treatment may be applicable for intractable neurological diseases, including HIE and MMC, during the perinatal period. In this review, we focus on recent research related to the therapeutic potential of AFS for perinatal neurological diseases such as HIE and MMC.

KW - amniotic fluid stem cells

KW - hypoxic-ischemic encephalopathy

KW - mesenchymal stem cells

KW - myelomeningocele

KW - perinatal medicine

UR - http://www.scopus.com/inward/record.url?scp=85052491923&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052491923&partnerID=8YFLogxK

U2 - 10.2302/kjm.2017-0019-IR

DO - 10.2302/kjm.2017-0019-IR

M3 - Article

C2 - 29515049

AN - SCOPUS:85052491923

VL - 67

SP - 57

EP - 66

JO - Keio Journal of Medicine

JF - Keio Journal of Medicine

SN - 0022-9717

IS - 4

ER -